GSK Remains Confident Despite RSV Vaccine Uptake Challenges and Shingrix Sales Decline ###

GSK's Confidence in RSV Vaccine::
Despite challenges in the rollout of its RSV vaccine, Arexvy, GSK remains confident in its peak sales potential.

Shingrix Sales Drop::
Shingrix, GSK's shingles vaccine, experienced a 36% drop in US sales during the second quarter of 2024.

CDC Guidelines Impact::
The Centers for Disease Control and Prevention (CDC) updated guidelines for RSV vaccines, limiting their use to seniors 75 years and older, and those at risk in the 60-74 age group.

Full-Year Vaccine Guidance Adjustment::
GSK lowered its full-year vaccine revenue guidance due to disappointing Q2 sales, now expecting low- to mid-single-digit percent growth.

Overall Business Performance::
Despite vaccine sales challenges, GSK's overall sales grew by 13% in Q2, with the Specialty Medicines unit performing well and a significant increase in oncology portfolio sales.